Aehr Test Systems stands to benefit as testing takes a larger share of expanding semiconductor capex. Teradyne CEO Greg Smith says test's share of semiconductor capex rose from 6.4% in 2025 to 8.1% in the first eight months of 2026, with conditions favorable for prolonged ATE growth. Data-center reliability is pushing testing upstream from systems toward packages and wafers, where Aehr dominates wafer-level burn-in. Aehr lacks a dedicated CPU segment. x.com 

Advantest beat because it simply grew at its own historical upcycle pace, which Wall Street underestimated. Revenue came in at ¥367B versus ¥336B consensus and a ¥360B forecast; analysts modeled just 2.3% sequential growth, while Advantest's median in an upcycle is closer to 10%. Earlier reports from Teradyne, TSMC and Disco had already signaled HBM4 pulling tester demand forward; Teradyne memory-test revenue below $170M or an AI mix under 65% would have broken that chain. x.com 

Advantest looks expensive even on peak-cycle earnings, at about 40 times its 2028 earnings. @holden_commodor argues testing is the ultimate semiconductor bottleneck after memory, with Advantest dominant ahead of Teradyne, and would buy if the drop continues. x.com 

Aehr remains a concentrated, expensive way to own wafer-level photonics burn-in: its 10-K says silicon-photonics customers primarily drove that revenue growth, and FY2027 guidance of $130m-$150m could nearly triple FY2026 sales, yet shares value it at about 20x the guide. Teradyne's acquired photonic-chip test business is not material to its much larger sales; Aehr's top five customers provided 70% of FY2026 revenue, so orders matter more than the headline CPO opportunity. x.com 

Aehr's AI burn-in growth case is intact, but confidence in its competitive edge may need to come down as Teradyne moves into high-power burn-in. Teradyne's Titan HP, already in production, combines system-level test and burn-in and could absorb spending on dedicated tools, pressuring Sonoma orders and pricing. Aehr still won about $6M of follow-on Sonoma orders for a hyperscaler's second AI chip, with no sign FOX-XP is replaced. If the market expands enough, revenue can grow as share falls. … Show more

Aehr Test Systems stands to benefit because testing is a bottleneck to scaling AI chips. Testing demand is about to surge. Investors did not question its price-to-sales ratio at 120, despite the current P/S objection. x.com  x.com 

Teradyne supplies the testing behind the AI revolution, with fundamentals accelerating and technicals confirming. x.com 

Aehr Test Systems' lead hyperscale customer is expanding production with about $6M of follow-on Sonoma orders for a second-generation AI processor. These are production-capacity orders, not evaluations, and the customer expects the second processor eventually to exceed the volumes of the first, already in high-volume production. Teradyne's new burn-in on Titan HP overlaps only with package-level Sonoma work, not FOX-XP wafer-level burn-in that screens dies before costly CoWoS packaging. x.com 

Aehr Test Systems' selloff has been excessive, despite concern about Teradyne expanding into burn-in, given where the two actually compete, as @LIWEI_TWCapital's comparison shows. x.com 

Teradyne's test business is surging because rising AI chip complexity multiplies testing demand. Q2 revenue was a record $1.329 billion, up about 104% and above consensus, and Semiconductor Test revenue rose 128% to $1.122 billion. Management said AI is now its primary growth engine, contributing about $1.2 billion of Q2 revenue across compute, HBM and networking. More sophisticated GPUs, ASICs and HBM need far more testing, making its high-end ATE mission-critical. x.com